Cancer has long been medicine’s most elusive target, but a wave of new research suggests scientists may finally be closing in ...

At the Cleveland Clinic, researchers are testing a preventive breast cancer vaccine, and results from Phase 1 of the trial are showing promising signs.

An analysis of ongoing trials suggests that mRNA cancer vaccines have the potential to deliver health benefits worth $75 ...

A groundbreaking lung cancer vaccine will be tested on humans from summer 2026, with British scientists working on jabs for ...

The fear of cancer stems from the dread that it can recur at any time, even after treatment. A South Korean research team has ...

Some cancer patients at The University of Texas MD Anderson Cancer Center got an unexpected boost. After receiving the ...

The trial targeting triple-negative breast cancer, which disproportionately affects Black women, induced immune responses in nearly three-quarters of participants.

Cleveland Clinic released its findings from the first phase of the clinical trial for the preventive breast cancer vaccine.

With enrollment completed and encouraging immune response and safety data observed in the Phase 1 trial, Anixa plans to advance the vaccine into a Phase 2 clinical trial and has assumed full ...

Last August, Labroots covered the decision of the National Health Service of England (NHS England) to allow subcutaneous (under the skin) injections of programmed death ligand 1 (PD-L1) blocker called ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...